Sanofi (NASDAQ:SNY) Stock Holdings Increased by Brandes Investment Partners LP

Brandes Investment Partners LP increased its holdings in Sanofi (NASDAQ:SNY) by 3.6% during the fourth quarter, Holdings Channel reports. The firm owned 2,194,938 shares of the company’s stock after purchasing an additional 76,092 shares during the period. Brandes Investment Partners LP’s holdings in Sanofi were worth $105,862,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Abel Hall LLC raised its holdings in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after acquiring an additional 194 shares during the period. Keudell Morrison Wealth Management raised its holdings in shares of Sanofi by 1.7% during the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares during the period. Bailard Inc. raised its holdings in shares of Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after acquiring an additional 220 shares during the period. Old Port Advisors raised its holdings in shares of Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after acquiring an additional 232 shares during the period. Finally, ORG Partners LLC raised its holdings in shares of Sanofi by 17.7% during the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock valued at $81,000 after acquiring an additional 253 shares during the period. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Sanofi stock opened at $57.75 on Friday. The firm has a market cap of $146.56 billion, a PE ratio of 23.19, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm’s 50 day moving average price is $53.65 and its two-hundred day moving average price is $52.86. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.